The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for Pebrilzo, a pertuzumab biosimilar developed by Biocon Biologics for HER2-positive breast cancer, Biocon announced on 21 September 2026, as reported by PTI through Rediff and by Whalesbook. The product is a 420 mg concentrate for solution for infusion. The application was submitted by Biocon Biologics Ireland Ltd, an indirect wholly owned subsidiary.
A CHMP opinion is a recommendation, not an approval. The European Commission now conducts the final review and decides whether to grant a marketing authorisation valid across the European Union, and Biocon itself states that the product will not be authorised for use in the EU until that decision is made. The opinion has no effect in the UK, where the MHRA is the licensing authority.
The EMA dates the committee's decision to 17th September 2026, with its public summary first published on 18th September. These dates distinguish the regulatory milestone from the subsequent company announcement. The agency identifies Perjeta as Pebrilzo's reference medicine.
What makes this opinion different
Biocon says Pebrilzo is the first monoclonal antibody biosimilar to receive a positive CHMP opinion under the EMA's new tailored clinical development approach. That approach reduces the clinical trial evidence a biosimilar must generate when analytical and pharmacological comparison with the reference medicine is strong enough. If other applicants follow the same route, the time and cost of bringing antibody biosimilars to the European market could fall, which is the main reason the opinion matters beyond one product.
What the tailored approach changes
Biosimilar development asks whether a medicine is sufficiently similar to an established biological treatment to rely on the knowledge already gained about that reference product. The comparison examines the medicine's characteristics and biological activity, alongside evidence about its behaviour in the body. It is a different scientific task from establishing the benefits of an entirely new cancer treatment.
The EMA's tailored framework allows comparative clinical efficacy studies to be waived or modified when analytical and pharmacokinetic or pharmacodynamic evidence provides sufficient assurance of biosimilarity. Pharmacokinetics concerns how the body handles a medicine; pharmacodynamics concerns its effects. The extent of clinical testing therefore depends on the uncertainty that remains after the other comparisons.
For Pebrilzo, the eventual assessment report will be particularly useful in showing how that principle was applied. The announcement alone does not establish precisely which studies were performed, which were considered unnecessary, or how each remaining scientific question was resolved. The claim about being first under this approach should continue to be attributed to Biocon.
The intended use
According to the company, Pebrilzo is intended for use in combination with other therapies, such as trastuzumab and chemotherapy, in adults with HER2-positive early, locally advanced or metastatic breast cancer. Those are the settings in which the reference medicine, pertuzumab, is already used. A biosimilar is expected to match its reference product in quality, safety and efficacy, and the committee's opinion indicates it found the evidence sufficient for Pebrilzo. The reports do not include the comparative data behind that opinion.
Which breast cancer settings are covered?
The EMA's published recommendation is more specific than the broad description of treatment across multiple disease stages. Before surgery, the proposed use combines Pebrilzo with trastuzumab and chemotherapy for HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence. After surgery, the proposed use covers HER2-positive early breast cancer at high risk of recurrence.
For metastatic disease, or cancer that has returned locally and cannot be removed surgically, the proposed combination is Pebrilzo, trastuzumab and docetaxel. This indication is limited to adults who have not previously received anti-HER2 treatment or chemotherapy for their metastatic disease. These distinctions matter because the recommendation does not cover every breast cancer diagnosis or every treatment sequence.
Why pertuzumab is combined with trastuzumab
Pertuzumab and trastuzumab both target HER2, a protein involved in signals that encourage cancer cells to grow. They attach to different parts of that protein and have complementary effects. The combination therefore blocks HER2 signalling in more than one way, while also helping the immune system act against cancer cells.
The distinction between the medicines also explains why a pertuzumab biosimilar does not replace every component of a combination regimen. Trastuzumab and any specified chemotherapy remain separate parts of the proposed treatment.
There is a further difference between formulations. Pebrilzo's proposed presentation is a concentrate for intravenous infusion. Phesgo, an existing treatment, combines pertuzumab and trastuzumab in an injection given under the skin. A pertuzumab infusion product should therefore not be described as a biosimilar version of that combined injection. The shared involvement of pertuzumab does not make the products identical in composition or administration.
Supply and competition
Whalesbook reports that Biocon's manufacturing site in Malaysia has recently gained approval for a second drug product line, designed to double capacity and support commercial supply from the second quarter of the company's 2027 financial year. The European biosimilar market is already crowded, with established producers such as Sandoz among the companies Biocon competes with, and pricing will decide how much of the pertuzumab market a new entrant takes.
The Malaysia expansion needs to be understood separately from the Pebrilzo application. Biocon describes its Malaysian facility as an insulin manufacturing operation, and its announcements about the new fill-finish unit concern insulins. That investment provides context for the company's wider manufacturing business, but does not establish where Pebrilzo will be produced or how much pertuzumab supply will be available in Europe.
Price will also be one part of the commercial picture. Authorisation and access involve different decisions: many European markets have national pricing and reimbursement procedures that medicines must pass through before routine funded use. A positive Commission decision would therefore not, by itself, mean a simultaneous launch in every country.
Given the different administration formats already available, an eventual comparison of treatment costs would also need to consider medicine preparation, staff time and infusion capacity. This is a practical implication of the formulations, rather than an established cost advantage for Pebrilzo. No quantified saving should be inferred from the CHMP opinion.
What biosimilarity means for treatment decisions
The EMA and the Heads of Medicines Agencies consider biosimilars approved in the EU interchangeable with their reference medicines from a scientific perspective. That position supports the use of an authorised biosimilar in place of its reference product, but national authorities determine policies on automatic substitution. It does not mean that a positive CHMP opinion alone permits a treatment change.
Biosimilar status also does not remove the precautions associated with the underlying therapy. Perjeta's product information addresses cardiac dysfunction and infusion or hypersensitivity reactions, among other risks. Those established concerns explain why the full prescribing information, appropriate monitoring and specialist oversight remain important when a pertuzumab product enters clinical use. Pebrilzo's final product information will set out its own authorised requirements.
What happens next
The European Commission decision is the next step, and Commission decisions usually follow CHMP opinions within about two months. What remains unknown is the comparative data the committee reviewed, which will appear in the European public assessment report once the Commission acts, and whether Biocon will seek a separate UK licence from the MHRA. Clinicians and patients should not treat the opinion as availability.
